MX2015007053A - Compuestos dimericos. - Google Patents

Compuestos dimericos.

Info

Publication number
MX2015007053A
MX2015007053A MX2015007053A MX2015007053A MX2015007053A MX 2015007053 A MX2015007053 A MX 2015007053A MX 2015007053 A MX2015007053 A MX 2015007053A MX 2015007053 A MX2015007053 A MX 2015007053A MX 2015007053 A MX2015007053 A MX 2015007053A
Authority
MX
Mexico
Prior art keywords
dimeric compounds
compounds
dimeric
cancer
formula
Prior art date
Application number
MX2015007053A
Other languages
English (en)
Inventor
Steven Gregory Mischke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015007053A publication Critical patent/MX2015007053A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)

Abstract

Se dan a conocer compuestos de fórmula I: (ver Fórmula) o sales farmacéuticamente aceptables de los mismos, en los que Z, X, Q y R1 se definen en la presente solicitud, y métodos de utilización de dichos compuestos en el tratamiento del cáncer.
MX2015007053A 2012-12-11 2013-12-09 Compuestos dimericos. MX2015007053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261735684P 2012-12-11 2012-12-11
PCT/EP2013/075874 WO2014090709A1 (en) 2012-12-11 2013-12-09 Dimeric compounds

Publications (1)

Publication Number Publication Date
MX2015007053A true MX2015007053A (es) 2015-09-28

Family

ID=49726780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007053A MX2015007053A (es) 2012-12-11 2013-12-09 Compuestos dimericos.

Country Status (19)

Country Link
US (1) US9409888B2 (es)
EP (1) EP2931719B1 (es)
JP (1) JP6309536B2 (es)
KR (1) KR20150093228A (es)
CN (1) CN104854100B (es)
AU (1) AU2013357493A1 (es)
CA (1) CA2887497A1 (es)
CL (1) CL2015001374A1 (es)
CO (1) CO7350640A2 (es)
CR (1) CR20150211A (es)
EA (1) EA201591024A1 (es)
HK (1) HK1213543A1 (es)
IL (1) IL238968A0 (es)
MA (1) MA38240B1 (es)
MX (1) MX2015007053A (es)
PE (1) PE20151083A1 (es)
PH (1) PH12015501088A1 (es)
SG (1) SG11201503718QA (es)
WO (1) WO2014090709A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
JP6302912B2 (ja) * 2012-09-19 2018-03-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 2−オキソ−2,3,4,5−テトラヒドロ−1h−ベンゾ[b]ジアゼピン及びがんの治療におけるその使用
MX2016006432A (es) 2013-11-18 2016-07-19 Hoffmann La Roche Tetrahidro-benzodiazepinonas.
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
JP6787331B2 (ja) * 2015-10-02 2020-11-18 日本ゼオン株式会社 酸ハライド溶液の製造方法、混合溶液、及びモノエステル化合物の製造方法
JP2019514878A (ja) 2016-04-20 2019-06-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Ripk2阻害剤を含むコンジュゲート
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック, インコーポレイテッド Protac抗体コンジュゲート及び使用方法
WO2023031801A1 (en) 2021-09-01 2023-03-09 Novartis Ag Bifunctional degraders comprising a tead binder
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201402124A (zh) * 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
AU2008321770B2 (en) * 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
EP2784076A1 (en) * 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
JP6302912B2 (ja) * 2012-09-19 2018-03-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 2−オキソ−2,3,4,5−テトラヒドロ−1h−ベンゾ[b]ジアゼピン及びがんの治療におけるその使用

Also Published As

Publication number Publication date
WO2014090709A1 (en) 2014-06-19
CN104854100B (zh) 2017-05-24
JP6309536B2 (ja) 2018-04-11
MA38240A1 (fr) 2018-02-28
MA38240B1 (fr) 2018-09-28
CL2015001374A1 (es) 2015-09-25
JP2016502986A (ja) 2016-02-01
HK1213543A1 (zh) 2016-07-08
IL238968A0 (en) 2015-07-30
CA2887497A1 (en) 2014-06-19
US9409888B2 (en) 2016-08-09
CN104854100A (zh) 2015-08-19
CR20150211A (es) 2015-05-29
EP2931719A1 (en) 2015-10-21
EA201591024A1 (ru) 2015-09-30
EP2931719B1 (en) 2017-01-25
PH12015501088A1 (en) 2015-08-03
US20160024055A1 (en) 2016-01-28
SG11201503718QA (en) 2015-06-29
PE20151083A1 (es) 2015-08-06
CO7350640A2 (es) 2015-08-10
AU2013357493A1 (en) 2015-04-30
KR20150093228A (ko) 2015-08-17

Similar Documents

Publication Publication Date Title
PH12015501088A1 (en) Dimeric compounds
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
IN2015DN01156A (es)
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MY177344A (en) Compounds and their methods of use
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
EA201171367A1 (ru) Винилиндазолильные соединения
EA201400178A1 (ru) Лечение рака молочной железы
GB201106750D0 (en) Novel compounds
PH12015501609A1 (en) Phenicol antibacterials
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
IN2015DN01119A (es)
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
GB201209587D0 (en) Therapeutic compounds
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
PH12015501038A1 (en) Inhibitors of iap
UA115357C2 (uk) Похідні піридин-4-ілу
MX2014009750A (es) Composiciones antifungicas para el tratamiento de piel y uñas.
PH12015500399A1 (en) Azaindolines
PH12015500185B1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
IN2014DN10669A (es)
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
MX348758B (es) Derivados de sanglifehrina y metodos para su produccion.